Breye Therapeutics ApS

Breye Therapeutics is a clinical stage biopharmaceutical company headquartered in Denmark pursuing a mission to develop novel oral therapies for the treatment of retinal vascular diseases. The Company is developing de-risked, safe and novel small molecules suited for oral administration which have a strong scientific rationale for treating diseases such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). Breye raised a seed round from Novo Holdings and Sound BioVentures and received financial support from the BioInnovation Institute, the Danish Growth Foundation (Vækstfonden) and the Danish Innovation Foundation (Innovationsfonden).

Contact name:

Ulrik Mouritzen, CEO


Agern Allé 24, 2970 Hørsholm , Denmark


+45 29604908



Number of employees:


If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact or +45 7172 1114

Copyright 2022 DANISH BIO – DANSK BIOTEK. All rights reserved.